UnitedHealthcare · Veozah Vms · US health-plan appeal rights

Veozah Vms denied for failing step therapy by UnitedHealthcare?

Q: How long do I have to appeal a UnitedHealthcare Veozah Vms denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Step-therapy denials usually flip when the appeal documents that prior alternatives were tried and failed, or were contraindicated, or aren't safe for the patient.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-10

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What UnitedHealthcare typically requires

UnitedHealthcare's specific coverage criteria for veozah vms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: OptumRx Prior Authorization — Veozah (Fezolinetant) for VMS

The UnitedHealthcare angle on Veozah Vms

## Why UHC Applies Step Therapy to Veozah for VMS

Veozah (fezolinetant) is a non-hormonal, NK3 receptor antagonist for moderate-to-severe vasomotor symptoms (VMS) due to menopause. UnitedHealthcare's step-therapy protocol for VMS typically requires documented trial and failure of — or a documented clinical reason to bypass — lower-cost or preferred formulary treatments before Veozah will be authorized. The most common required steps are hormone therapy (estrogen with or without progestin) and/or other non-hormonal agents that appear on the UHC formulary. The denial indicates that UHC's records do not reflect a completed required step.

## Why This Is Appealable

Step-therapy override rights are among the most widely recognized in insurance law. Federal rules and most state step-therapy statutes require an insurer to grant an exception when: (a) the required first-step therapy is contraindicated or clinically inappropriate for the specific patient; (b) the patient already tried and failed the required step; (c) the required step would cause clinically significant delay or harm; or (d) the patient has a condition — such as a history of hormone-sensitive cancer — that makes hormonal therapy medically inappropriate. Fezolinetant's distinct mechanism (non-hormonal, central NK3 blockade) is particularly relevant when HT is contraindicated.

## Federal Appeal Framework

Step-therapy exception request: File a formal step-therapy override request alongside or before the internal appeal. Most states require a decision within 72 hours (expedited) or a short standard window. UHC must provide the specific steps required and the criteria for an exception.
Internal appeal (ACA/ERISA §503): If the exception is denied, you have a full internal appeal right. Request the exact step-therapy policy UHC applied.
External review (ACA §2719): After a final internal denial, request independent external review within approximately four months. External reviewers apply clinical standards and step-therapy override criteria independently of UHC's formulary preferences.

## Documentation to Gather

1. Required steps completed: For each drug UHC's step-therapy policy requires, document: dates of trial, drug name, duration, and the specific outcome (inadequate response, intolerance with description of adverse effects, or contraindication). 2. Hormone therapy contraindication (if applicable): If HT is the required first step and is clinically inappropriate, document the specific clinical reason — for example, hormone-receptor-positive cancer history, cardiovascular risk factors, or other conditions addressed in the relevant professional society guideline (e.g., NAMS). 3. Urgency of treatment: If completing a step-therapy trial would cause clinically significant delay or harm — for example, severely disruptive VMS affecting patient safety, sleep, or a critical work function — the prescriber should document this. 4. Prescriber medical-necessity letter: Should address each override criterion in UHC's step-therapy policy; explain why Veozah is the appropriate treatment at this stage; and reference the FDA-approved prescribing label and the NAMS (Menopause Society) guideline on non-hormonal VMS treatment. 5. UHC step-therapy policy: Obtain the current policy to confirm which steps are required and what the override criteria are — then address every criterion explicitly in the appeal.

## Criteria-Mapping Structure for Your Appeal Letter

| Step-Therapy Requirement | Override Basis / Chart Evidence | |---|---| | Trial of hormone therapy | Dates, outcomes — or documented contraindication with clinical rationale | | Trial of preferred non-hormonal formulary agent | Dates, outcomes — or clinical reason the agent was not appropriate | | Minimum duration of required step | Duration completed — or reason it was unsafe or futile to continue | | Prescriber supports Veozah as next step | Letter from treating clinician with step-by-step rationale |

A letter that names each required step, confirms it was completed or overridden with clinical justification, and cites the applicable override criteria by name is the most effective format for this denial type.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other UnitedHealthcare appeals

Other denial reasons for UnitedHealthcare Veozah Vms

denied as not medically necessary denied as non-formulary denied for missing prior authorization denied as experimental or investigational denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-10. Editorial standards: denialhelp.com/authors.